Search
News & Events
Meet the Researcher: Dr Gina TrappDr Gina Trapp is the Head of Food and Nutrition – driven to leading her team in becoming a hub of child and adolescent nutrition research globally.
News & Events
Meet Shakara - STARS Award RecipientShakara Liddelow-Hunt secured STARS funding to attend a two-day workshop, Start Talking About Relationships & Sexual Health Training.
Read the 2024 edition of the Together Magazine
Research
Oombarl Oombarl Joorrinygor-Slowly Slowly Moving Forward: Reflections From a Cross-Cultural Team Working Together on the See, Treat, Prevent (SToP) Trial in the Kimberley Region of WAReflexivity is crucial for researchers and health professionals working within Aboriginal health. Reflexivity provides a tool for non-Aboriginal researchers to contribute to the broader intention of reframing historical academic positivist paradigms into Indigenous research methodologies to privilege Aboriginal voices in knowledge construction and decision-making.
Research
The parent empowerment scale: development and psychometric propertiesParents of trans and gender diverse (herein ‘trans’) children experience additional challenges in their parenting role relative to parents of cisgender children. Understanding and enhancing parents’ empowerment is a promising approach to support both parents and children. We aimed to develop an empowerment scale specific to parents of trans children, grounded in parents’ lived experiences.
Research
Developmental queer and trans actualizations: A clear pathway to promoting health and well-being for sexually and gender diverse youthMinority stress models and trauma-focused approaches have predominated our understanding and responses to health disparities among sexually and gender diverse (SGD) young people for more than 30 years. While the impacts and root causes of adversities are undoubtedly critical for promoting SGD health and well-being, it is important to highlight strengths-based narratives of the lives of SGD youth.
Research
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case seriesEnsitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.
Research
Corrigendum to “A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 comparedPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group